
|Articles|October 31, 2022
Massive Bio Onboards Over 100,000 Cancer Patients
Advertisement
Massive Bio announced that the company exceeded its goal to onboard 100,000 cancer patients in its platform by the end of 2022. The Massive Bio platform matches cancer patients with relevant clinical trials using AI.
Read more about the platform and its enrollment
.
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Beyond Patient Centricity: What Rare Disease Research Gets Right
2
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
3
ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD
4
The Unquantified Value of RBQM: Reduced Rework, Data Integrity, and Inspection Readiness
5




